<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071366</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 39110-211</org_study_id>
    <nct_id>NCT04071366</nct_id>
  </id_info>
  <brief_title>A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy</brief_title>
  <official_title>A Phase 2, Single-Arm, Open-Label Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of oral administration of
      itacitinib once daily for the prevention of cytokine release syndrome (CRS) in male or female
      participants aged 12 years or older and who are planning to receive tisagenlecleucel or
      axicabtagene ciloleucel immune effector cell (IEC) therapy for any approved hematologic
      indication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who develop ≥ Grade 2 CRS</measure>
    <time_frame>Day 14</time_frame>
    <description>Assessed using American Society for Blood and Marrow Transplantation (ASBMT) CRS Consensus Grading.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with immune effector cell-associated neurotoxicity syndrome (ICANS) after IEC therapy</measure>
    <time_frame>Day 28</time_frame>
    <description>Assessed using the ICANS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICANS regardless of CRS</measure>
    <time_frame>Day 28</time_frame>
    <description>Assessed using the ICANS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of all grades of CRS</measure>
    <time_frame>Day 28</time_frame>
    <description>Assessed using ASBMT CRS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with any grade of CRS after IEC therapy</measure>
    <time_frame>48 hours</time_frame>
    <description>Assessed using ASBMT CRS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥ Grade 2 CRS after first IEC therapy</measure>
    <time_frame>Day 28</time_frame>
    <description>Assessed using ASBMT CRS Consensus Grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>Day -3 through safety follow-up, up to approximately 60 days.</time_frame>
    <description>Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of itacitinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions for participants with CRS and/or ICANS</measure>
    <time_frame>Through end of study, up to 180 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay for participants with CRS and/or ICANS</measure>
    <time_frame>Through end of study, up to 180 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Cytokine Release Syndrome</condition>
  <arm_group>
    <arm_group_label>Itacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>Itacitinib 200 mg once daily for 30 days.</description>
    <arm_group_label>Itacitinib</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune effector cell therapy</intervention_name>
    <description>Tisagenlecleucel or axicabtagene ciloleucel administered per prescribing label on Day 0.</description>
    <arm_group_label>Itacitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible to receive either tisagenlecleucel or axicabtagene ciloleucel for approved
             hematologic indications.

          -  Eastern Cooperative Oncology Group performance status 0 to 1.

          -  Willingness to avoid pregnancy or fathering children

        Exclusion Criteria:

          -  Evidence of active uncontrolled/untreated infection (viral, bacterial, fungal,
             opportunistic) of any origin.

          -  Evidence of active hepatitis B virus or hepatitis C virus infection.

          -  Known human immunodeficiency virus.

          -  Active acute or chronic graft-versus-host disease requiring systemic therapy.

          -  Concurrent use of chronic systemic steroids or immunosuppressant medications.

          -  Any unresolved toxicity ≥ Grade 2 (except stable Grade 2 peripheral neuropathy or
             alopecia) from previous anticancer therapy.

          -  Known history or prior diagnosis of immunologic or inflammatory/autoimmune disease
             affecting the central nervous system (CNS) and unrelated to their disease under study
             or previous treatment.

          -  Clinically significant or uncontrolled cardiac disease.

          -  Acute lymphoblastic leukemia participants with protocol-defined CNS status are
             eligible only in the absence of neurologic symptoms suggestive of CNS leukemia.

          -  Diffuse large B-cell lymphoma participants must have no signs or symptoms of CNS
             disease or detectable evidence of CNS disease; participants who have been previously
             treated for CNS disease but have no evidence of disease at screening are eligible.

          -  Laboratory values at screening outside the protocol-defined ranges.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Langmuir, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univ. of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Univ. School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Univ. Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science Universtiy</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ. of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytokine release syndrome</keyword>
  <keyword>immune effector cell-associated neurotoxicity syndrome</keyword>
  <keyword>Janus kinase inhibitor</keyword>
  <keyword>tisagenlecleucel</keyword>
  <keyword>axicabtagene ciloleucel</keyword>
  <keyword>immune effector cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

